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Abstract:  Cranberries are rich in bioactive constituents purported to enhance immune 
function, improve urinary tract health, reduce cardiovascular disease and more recently, 
inhibit cancer in preclinical models. However, identification of the cranberry constituents 
with the strongest cancer inhibitory potential and the mechanism associated with cancer 
inhibition by cranberries remains to be elucidated. This study investigated the ability of a 
proanthocyanidin rich cranberry fraction (PAC) to alter gene expression, induce apoptosis 
and impact the cell cycle machinery of human NCI-H460 lung cancer cells. Lung cancer is 
the leading cause of cancer-related deaths in the United States and five year survival rates 
remain poor at 16%. Thus, assessing potential inhibitors of lung cancer-linked signaling 
pathways is an active area of investigation.  
Keywords:  cranberry; tannins; proanthocyanidins; flavan-3-ols; apoptosis; cancer cells; 
global gene expression; cell cycle 
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1. Introduction  
Lung cancer is the leading cause of cancer related death among men and women in the United 
States and despite recent advances in treatment overall prognosis remains poor [1]. The development 
of effective agents for the prevention and treatment of lung cancer is an active area of investigation. 
Smoking is the principal cause of lung cancer [2]; however, risk increases with exposure to second 
hand smoke, radon, asbestos, radiation, arsenic, aluminum, chromium, cadmium and select organic 
chemicals [3]. The potential protective role of diet in lung cancer is still being unraveled. To date, 
epidemiological studies strongly support that diets rich in fruits may reduce lung cancer risk, as 
extensively reviewed in the World Cancer Research Fund report [4]. Fruits contain a multitude of 
bioactive food constituents with pleiotropic health benefits. Cranberries (Vaccinium macrocarpon 
Ait.), for example, reportedly have antimicrobial, antiviral and more recently, anticancer functions  
[5-17]. The current study sought to investigate potential cancer inhibitory mechanisms associated with 
a proanthocyanidin rich cranberry fraction (PAC) in “resistant” lung cancer cells. The investigation of 
such food-derived agents holds particular promise given the repeated negative results of 
vitamin/mineral/antioxidant supplementation trials in at risk cohorts [18-21]. Promising food-derived 
agents with cancer inhibitory effects supplied at behaviorally achievable levels are likely to be well 
tolerated and safe. These are important considerations for relatively healthy cohorts who may consume 
cancer protective agents for extended periods to derive maximum health benefits. Understanding the 
specific mechanisms of cancer inhibition is important not only for preventive interventions, but may 
hold promise for reversing a “resistant” phenotype prior to cancer chemotherapy.  
2. Results and Discussion  
2.1. Modulation of global gene expression patterns by PAC 
To explore the mechanisms and signaling cascades linked to the cancer inhibitory potential of PAC 
we utilized global gene expression analysis of NCI-H460 human lung cancer cells which were treated 
with 50 µg/mL PAC or vehicle for 6 hours. This concentration of PAC was chosen based on earlier 
work which had determined the IC50 to be 50 µg/mL [17]. Ease analysis was employed to investigate 
the effects of PAC on over-represented Gene Ontology (GO) categories (Table 1). The top 30 
biological processes down-or up-regulated greater than 2-fold are displayed in Table 1. As shown a 
large number of processes linked to cell death were significantly up-regulated by PAC treatment 
including regulation of apoptosis, regulation of programmed cell death, positive regulation of cell 
death, positive regulation of apoptosis, and apoptotic mitochondrial changes. The dominate biological 
processes down-regulated following PAC treatment included metabolism, protein modifications, and 
cell cycle linked processes as illustrated by down regulation of M phase of mitotic cell cycle, mitosis, 
M phase, cell cycle checkpoint, and regulation of cell cycle process. Figure 1 illustrates the cell cycle 
pathway in KEGG with red stars marking down-regulated markers following PAC treatment of NCI-
H460 cells compared to vehicle treated NCI-H460 cells. A number of cell cycle related markers were 
validated utilizing real time PCR and RT² Profiler PCR Arrays including, BCCIP, CCNB1, CCND1, 
CCNT1, CDC2, CDC16, CDC20, CDK4, CDK6, CDKN3, CHEK2, GTF2H1, HUS1, KNTC1, 
MAD2L1, MCM5, MKI67, MNAT, MRE11A, PCNA, RAD1, RAD17, SERTAD1, SUMO1 and Molecules 2011, 16                                       
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TFDP1. Further evaluation of signaling pathways utilizing PANTHER further supported the general 
alterations noted on gene ontology categories. Detoxification processes were up-regulated by PAC 
treatment, as a number of glutathione S-tranferases were significantly increased. PAC treatment also 
down-regulated DNA metabolism, cell cycle, meiosis, mitosis and interestingly oncogenesis signaling. 
In addition, analysis of KEGG pathways following PAC treatment revealed effects on erbB and mTor 
signaling, pathways altered in lung carcinogenesis [22,23].  
Table 1. Over-represented gene ontology categories deregulated in NCI-H460 cells by PAC treatment. 
Up-Regulated  
Biological Processes (n = 30/221) 
%  P-ValueDown-Regulated  
Biological Processes (n = 30/207) 
%  P-Value
Protein transport  5.89  7.2E-11 RNA metabolic process  7.46  9.5E-21
RNA metabolic process  6.81  3.8E-09 Cellular protein metabolic process  15.79 1.4E-19
Cellular protein metabolic process  15.17 7.2E-09 RNA processing  4.61  8.9E-16
RNA processing  4.24  3.5E-08 M phase of mitotic cell cycle  2.21  1.1E-12
Intracellular protein transport  3.02 3.9E-07 Mitosis 2.16  2.1E-12
Golgi vesicle transport  1.27  4.3E-06 M phase  2.91  4.0E-12
RNA splicing  2.29  1.2E-05 DNA repair  2.59  6.5E-12
Cellular protein complex assembly  1.44  2.7E-05 Regulation of gene expression  17.66 1.3E-11
Protein modification process  9.24  5.2E-05 Regulation of macromolecule biosynthetic 
process 
17.51 1.4E-11
Regulation of gene expression, epigenetic  0.80  7.0E-05 mRNA metabolic process  3.13  3.8E-11
Regulation of apoptosis  5.37  1.2E-04 DNA metabolic process  3.96  1.7E-10
ncRNA processing  1.56  1.2E-04 Modification-dependent macromolecule 
catabolic process 
4.37 3.1E-10
mRNA metabolic process  2.73  1.2E-04 mRNA processing  2.74  3.1E-10
phospholipid biosynthetic process  0.97  1.4E-04 Cellular protein catabolic process  4.54  3.9E-10
Regulation of programmed cell death  5.40  1.7E-04 Regulation of cellular biosynthetic process  17.91 4.3E-10
mRNA processing  2.40  1.9E-04 Regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic 
process 
17.14 8.0E-10
Positive regulation of cell death  3.09  3.0E-04 Protein catabolic process  4.61  1.6E-09
Negative regulation of macromolecule 
metabolic process 
4.88 3.5E-04 RNA  splicing  2.44 2.0E-09
Positive regulation of programmed cell 
death 
3.06 3.7E-04 Regulation  of  transcription  15.79 1.1E-08
Positive regulation of apoptosis  3.04  4.0E-04 Protein transport  5.25  1.5E-07
Apoptotic mitochondrial changes  0.40  4.3E-04 Protein modification process  9.15  5.5E-07
Glycerophospholipid biosynthetic process  0.68  5.3E-04 Cell cycle checkpoint  0.94  1.1E-06
Negative regulation of cellular metabolic 
process 
4.76  5.6E-04 Regulation of cell cycle process  1.07  6.2E-06
Chromatin modification  2.05  5.9E-04 Negative regulation of macromolecule 
metabolic process 
4.89 7.3E-06
ncRNA metabolic process  1.77  6.3E-04 DNA replication  1.56  1.3E-05
Actin filament organization  0.71  6.6E-04 Negative regulation of nucleobase, 
nucleoside, nucleotide and nucleic acid 
metabolic process 
3.51 2.7E-05
Induction of programmed cell death  2.31  1.1E-03 RNA biosynthetic process  2.21  2.9E-05
Heme metabolic process  0.31  1.2E-03 Translation  2.42  3.0E-05
Negative regulation of gene expression  3.42  1.2E-03 DNA damage response, signal transduction  0.79  3.1E-05
DNA metabolic process  3.42  1.4E-03 Negative regulation of gene expression  3.43  5.7E-05Molecules 2011, 16                                       
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Figure 1. Cell cycle pathway represented in KEGG [24,25]. Red stars mark genes down 
regulated following PAC treatment of NCI-H460 cells compared to vehicle treated cells 
based on global gene expression results. As illustrated, PAC alters expression of a large 
number of genes involved in all phases of cell cycle regulation, including the G1/S and 
G2/M transitions and DNA replication.  
 
2.2. Pac induces rapid and significant apoptosis in lung cancer cells 
Next, PACs cell death inducing effects were further investigated over time in lung cancer cells via 
Annexin V-FITC staining methods and flow cytometry. As Figure 2 shows, PAC treatment resulted in 
significant and rapid apoptosis induction, with maximal apoptosis of 6.29-fold occurring 6 hours post-
treatment. Total apoptosis occurred at 25.2, 55.7, 61.2, 55.6 and 21.4% at 2, 6, 12 and 24 hours, 
respectively. Specifically PAC induced early, late and total apoptosis following 2, 6, 12 and 24 hours 
of PAC treatment; however, by 48 hours there was a significant, but only modest 2.5 fold increase in 
total apoptosis supporting that the cells are starting to recovery from PACs cell death inducing effects 
at this late time-point. At 2 hours post-PAC treatment the majority of apoptosis is early, but rapidly 
shifts to late apoptosis by 6 hours. The data also shows significant reductions in “unstained” or live 
cells as displayed in the lower left quadrant of Figure 2B and 2C. The reductions in unstained vehicle 
versus PAC treated cells were 18.11, 48.19, 57.32, 48.91 and 13.74% at 2, 6, 12, 24, and 48 hours, 
respectively supporting that the greatest PAC-induced cell death occurs between 6 and 24 hours. The 
gene expression results coupled with these findings led us to further explore and validate specific Molecules 2011, 16                                       
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apoptotic markers utilizing real time PCR as described in the methods section. Table 2 summarizes the 
results of the validated apoptotic markers and their potential functions.  
Figure 2. PAC (50 μg/mL) induces cell death in NCI-H460 lung cancer cells. (A) 
summary of the effects of PAC on early, late and total apoptosis at 2, 6, 12, 24 and   
48 hours post-treatment as determined by Annexin V-FITC staining. PAC treatment 
induced significant early apoptosis (B and C, lower right quadrant), late apoptosis (upper 
right quadrant) and total apoptosis at 2, 6, 12, and 24 hours. The largest magnitude of 
apoptosis induction occurred following 6 and 12 hours of treatment as illustrated in (B) and 
(C). PAC induces significant necrosis (C, upper left quadrant) following 12 and 24 hours of 
PAC treatment as evidenced by the increase from <1.00% necrosis in vehicle treated NCI-
H460 cells to 6.98% in PAC treated cells 12 hours post-exposure. The values represent 
means ±SD of three independent samples per experimental treatment and time-point   
(P < 0.05, two-tailed t test). Asterisks indicate a statistically significant difference between 
PAC and vehicle treated cells. Reported fold-change values refer to the fold-change 
induced by PAC treatment compared to vehicle in terms of total apoptosis induction.  
 
Time Point/Treatment
Early Apoptosis
(±SD) 
Late Apoptosis 
(±SD) 
Total Apoptosis 
(±SD) 
Fold-Change 
(P-Value) 
2 hrs NCI460-VEH 
 NCI460-PAC 
5.85% (0.33) 
13.83% (0.79)* 
1.56% (0.46) 
11.39% (2.65)* 
7.41% (0.78) 
25.22% (2.98)* 
3.40 
(1.35E-02) 
6 hrs NCI460-VEH 
 NCI460-PAC 
5.12% (0.49) 
16.49% (2.12)* 
3.73% (0.40) 
39.20% (2.65)* 
8.86% (0.87) 
55.69% (0.88)* 
6.29 
(3.06E-05) 
12 hrs NCI460-VEH 
 NCI460-PAC 
6.17% (1.06) 
13.70% (0.74)* 
4.58% (0.29) 
47.46% (3.53)* 
10.75% (1.18) 
61.16% (3.04)* 
5.69 
(6.49E-04) 
24 hrs NCI460-VEH 
 NCI460-PAC 
7.00% (1.08) 
16.87% (0.58)* 
5.03% (1.66) 
38.73% (1.84)* 
12.03% (2.31) 
55.60% (1.99)* 
4.62 
(4.81E-05) 
48 hrs NCI460-VEH 
 NCI460-PAC 
3.48% (0.50 
13.15% (1.87) 
4.94% (1.08) 
8.23% (1.08) 
8.42% (1.58) 
21.38% (1.47)* 
2.54 
(1.48E-02) 
6 Hr Post-Treatment
VEH                       PAC 
0.04% 3.73%
5.12%
1.40% 39.20%
16.49% 13.70%
47.46% 0.07% 4.58%
6.17%
6.98%
BC 12 Hr Post-Treatment
VEH                          PAC 
*
* *
*
*
91.10% 42.91%* 89.18% 31.86%*
 
In summary, PAC treatment resulted in rapid and significant induction of cell death in NCI-H460 
lung cancer cells. This line is known to express wild type p53 [26], but also has been documented to 
over-express X-linked inhibitor of apoptosis protein (XIAP) resulting in suppressed activation of 
downstream effector caspases and apoptotic resistance [27]. Resistance is problematic in the context of 
A Molecules 2011, 16                                       
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cancer prevention as well as chemotherapy; thus, it is particularly promising that PAC has potent cell 
death inducing effects in a “resistant” cell line. Furthermore, global gene expression results showed 
that PAC down-regulated expression of a number of inhibitor of apoptosis proteins (IAPs) including 
BIRC1, BIRC2, BIRC4 or XIAP, and BIRC6, many of which have been been linked to apoptosis 
resistance in the presence of anticancer drugs [28,29]. As shown in Table 2, PAC down-regulates a 
number of additional anti-apoptotic molecules, including BAG4, BNIP2, and BNIP3L. Conversely, the 
RT² Profiler PCR Apoptosis Array validated a number of pro-apoptotic markers [31,32] as up-
regulated following PAC treatment including BID, multiple pro-apoptotic TNF superfamily members 
and related adapter molecules, as well as p73 [33]. P73 is a p53 family member linked to cell death 
induction via apoptosis and type II cell death or autophagy [34]. Kim et al. reported that up-regulation 
of autophagy occurred following treatment with inhibitors of caspase-3 and mTOR resulting in 
enhanced radiosensitivity in a mouse model of lung cancer [35]. PAC treatment of NCI-H460 cell 
decreased pro-apoptotic, CASP3 [36] which may be linked to activation of type two cell death. PAC 
treatment up-regulated pro-apoptotic Bcl-2 family members [37] such as Bok, Bax, and Bad; the latter 
two molecules are known to be inactivated by tobacco specific carcinogens in lung epithelial cells [38-41]. 
Although further analysis of specific caspase molecules is warranted, the gene expression results 
coupled with the real-time PCR validation data support that apoptosis induction is mediated in part by 
the activation of death receptors belonging to the tumor necrosis factor receptor gene superfamily.  
Table 2. Apoptotic associated genes validated by real-time PCR as up- or down-regulated 
in NCI-H460 cells following PAC treatment.  
Up-Regulated by PAC Treatment (>2.0 fold) 
Gene   Name 
Fold-
Change
Function 
BCL2L10  BCL2-like 10 (apoptosis 
facilitator) 
+3.25  Anti-apoptotic member of the Bcl-2 family that blocks apoptosis 
in the mitochondrial death pathway, but not in the death receptor 
pathway [42]. 
BID BH3  interacting  domain 
death agonist 
+3.25  Pro-apoptotic member of Bcl-2 proteins and encodes a death 
agonist that heterodimerizes with either agonist BAX or 
antagonist BCL2.  
DFFA  DNA fragmentation factor  +2.00  A substrate for caspase-3 and triggers DNA fragmentation during
apoptosis [43]. 
MCL1  myeloid cell leukemia 
sequence 1 (BCL2-related) 
+2.00  Involved in the regulation of apoptosis versus cell survival and 
maintenance of viability, but not of proliferation. Two isoforms 
have been identified, isoform 1 inhibits apoptosis and isoform 2 
promotes apoptosis [44]. 
TNF  tumor necrosis factor  +9.19  Cytokine that binds to TNFRSF1A/TNFR1 and 
TNFRSF1B/TNFBR, involved in the regulation cell 
proliferation, differentiation, apoptosis, lipid metabolism, and 
coagulation. Induces cell death of certain tumor cell lines. 
TNFRSF10A  tumor necrosis factor 
receptor superfamily, 
member 10a 
+3.03 Transduces  cell  death signal and induces cell apoptosis via 
activation by tumor necrosis factor-related apoptosis inducing 
ligand (TNFSF10/TRAIL) [45]. 
TNFRSF25  tumor necrosis factor 
receptor superfamily, 
member 25 
+14.93 TNFSF12/APO3L/TWEAK  receptor, interacts directly with the 
TRADD, mediates activation of NF-kappa-B and induces 
apoptosis [46)]. Molecules 2011, 16                                       
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Table 2. Cont. 
TNFSF7  tumor necrosis factor 
receptor superfamily, 
member 7 
+2.83  Cytokine that binds to CD27 and involved in T-cell activation. 
Induces proliferation of co-stimulated T-cells and enhances the 
generation of cytolytic T-cells [47]. 
TP73  tumor protein P73  +22.63  Postulated tumor suppressor protein and p53 family member. 
Family members include p53, p63, and p73 and have high 
sequence similarity, which allows p63 and p73 to transactivate 
p53-responsive genes causing cell cycle arrest and apoptosis. 
[33]. 
TRADD TNFRSF1A-associated  via 
death domain 
+12.13  Adaptor molecule that interacts with TNFRSF1A/TNFR1 and 
mediates programmed cell death signaling and NF-kappaB 
activation. This protein reduces recruitment of inhibitor-of-
apoptosis proteins (IAPs) by TRAF2 [48].  
TRAF3 TNF  receptor-associated 
factor 3 
+2.43  Adapter protein and signal transducer that links members of the 
tumor necrosis factor receptor family to signaling pathways. 
Involved in the activation of NF-kappa-B and JNK and in 
apoptosis [49].  
Down-Regulated by PAC Treatment (>2.0 fold) 
Gene   Name  Fold-
Change
Function 
BAG4  BCL2-associated athanogene 4  -2.46  Member of the BAG1 anti-apoptotic protein family [31,32].  
XIAP  baculoviral IAP repeat-
containing protein 4 
-6.96  Apoptotic suppressor through binding to tumor necrosis factor 
receptor-associated factors TRAF1 and TRAF2 [28,29].  
BFAR bifunctional  apoptosis 
regulator 
-3.25  Apoptosis regulator with bifunctional anti-apoptotic activity for 
apoptosis triggered by death-receptors and mitochondrial factors 
[50]. 
BNIP2  BCL2/adenovirus E1B 19kDa 
interacting protein 2 
-6.50  Member of the BCL2/adenovirus E1B 19 kD-interacting protein 
family. Its specific function is unknown; however, it interacts 
with the E1B 19 kD protein which is responsible for the 
protection of virally-induced cell death, as well as E1B 19 kD-
like sequences of BCL2, an apoptotic protector [51]. 
BNIP3L BCL2/adenovirus  E1B19kDa 
interacting protein 3-like 
-3.25  Same as BNIP2. May also function as a tumor suppressor and 
inhibits apoptosis induced by BNIP3 [51,52]. 
CARD8 caspase  recruitment  domain 
family, member 8 
-3.73  Postulated to be a component of the inflammasome, a protein 
complex that plays a role in the activation of proinflammatory 
caspases. Also, acts as an adaptor molecule negatively regulating 
NFKB activation, CASP1-dependent IL1B secretion, and 
apoptosis [53].  
CASP3 caspase  3,  apoptosis-related 
cysteine peptidase 
-8.00  Involved in the activation cascade of caspases responsible for 
apoptosis execution. An effector caspases, responsible for 
cleaving downstream substrates [36].  
CASP4 caspase  4,  apoptosis-related 
cysteine peptidase 
-13.00  An initiator caspase able to cleave and activate its own precursor 
protein, as well as caspase 1 precursor. 
CRADD  CASP2 and RIPK1 domain 
containing adaptor with death 
domain 
-3.03  Apoptotic adaptor molecule specific for caspase-2 and 
FASL/TNF receptor-interacting protein RIP [54]. 
LTBR lymphotoxin  beta  receptor, 
TNFR superfamily member 3 
-2.83  Receptor for the heterotrimeric lymphotoxin containing LTA, 
LTB, and TNFS14/LIGHT. Pro-apoptotic via TRAF3 and 
TRAF5 [55,56]. Molecules 2011, 16                                       
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Table 2. Cont. 
TNFS8   tumor necrosis factor (ligand) 
superfamily, member 8 
-3.73  A cytokine that belongs to the tumor necrosis factor (TNF) 
ligand family and has been reported to induce cell proliferation 
[57]. 
TP53BP2  tumor protein p53 binding 
protein 
-5.66  Regulates apoptosis and cell growth through interactions with 
other p53 regulatory molecules. Inhibits the ability of APPBP1 to
conjugate NEDD8 to CUL1 decreasing apoptosis induction by 
APPBP1. Impedes cell cycle progression at G2/M checkpoint 
[58,59]. 
Next, a limited number of specific proteins were analyzed to further verify the effects of PAC on 
the apoptotic marker PARP1 and P21, an important mediator of cell cycle arrest as illustrated in Figure 
3. We have previously reported that PAC decreases S-phase and causes arrest of NCI-H460 cells at the 
G1 checkpoint; however, we have recently found that PAC can induce arrest at the G2 checkpoint in 
esophageal adenocarcinoma cells (EAC) (unpublished data) supporting that specific cell death 
inducing effects differ between cell lines, likely due to the molecular profile of the individual cell line 
under investigation. P21 is reported to mediate cell cycle arrest in response to the p53 checkpoint [60] 
and the NCI-H460 cell line expresses wild type p53; whereas p53 is mutated or deleted in our EAC 
cells. In addition, induced activation of p21 has been linked to lung cancer cell growth inhibition and 
enhanced chemosensitivity to cisplatin [61].  
Figure 3. PAC treatment is associated with time-dependent changes in the expression of 
cell cycle regulatory and apoptotic molecules. NCI-H460 cells (1.0 × 10
5 cells) were grown 
for 35 hours, rinsed with PBS, treated with PAC (50 µg/mL) in triplicate, harvested at 
various time points (0–72 hours), and subjected to immunoblot. Expression values were 
normalized to the appropriate loading control (GAPDH) and a fold-change from baseline 
or first detection level was calculated. A time-dependent increases in expression of P21 
was noted as early as 3 hours with maximal increased expression at 12–24 hours. A time 
course of increased expression of the apoptotic markers cytochrome C and PARP are 
shown. PARP cleavage was both time and dose dependent.  
0 Hr     3 Hr     6 Hr     12 Hr     24 Hr     48 Hr     72 Hr
25 µg/ml PAC
PARP, 166 kDa
Cleaved, 89 kDA
50 µg/ml PAC
GAPDH
PARP, 166 kDa
Cleaved, 89 kDA
50 µg/ml PAC Cytochrome C
1.0       1.1       1.2        1.3       1.3       1.2       1.3-Fold Increase
50 µg/ml PAC
1.0       1.8       2.4        2.3        2.2       1.5       1.7-Fold Increase
P21
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3. Experimental  
3.1. Cell cultures  
The lung adenocarcinoma cell line NCI-H460 originated from a non-small cell lung cancer of the 
large cell type and is available through American Type Culture Collection [62]. Cancer cells were 
grown in Dulbecco’s modification of Eagle’s medium (DMEM) containing L-glutamine (2.0 mM), 
penicillin (10
4 units/mL), sodium pyruvate (1 mM), and FBS (0-10%, depending on the experiment). 
Cells were maintained as monolayers (37 °C, 5% CO2, 95% air). 
3.2. Cranberry proanthocyanidins  
Cranberry fruit (Vaccinium macrocarpon Ait.) was collected at the Marcucci Center for Blueberry 
and Cranberry Research, Chatsworth, NJ, USA. The cranberry PAC-rich powder was prepared Dr. 
Amy Howell (Rutgers University, Chatsworth, NJ) as previously reported [63]. In brief, purified 
cranberry proanthocyanidin extract was isolated from cranberries of the ‘Early Black’ cultivar using 
solid-phase chromatography according to well-established methods [63-65]. The fruit was 
homogenized with 70% aqueous acetone, filtered, and the pulp was discarded. Acetone was removed 
and the cranberry extract was suspended in water, applied to a preconditioned C-18 solid phase 
chromatography column, and washed with water to remove sugars, followed by acidified aqueous 
methanol to remove acids. The fats and waxes were retained on the C-18 sorbent. The total 
polyphenolic fraction containing anthocyanins and flavonol glycosides as well as the 
proanthocyanidins (confirmed using reverse phase HPLC with diode array detection) was eluted with 
100% methanol and dried under reduced pressure. The total polyphenolic fraction was suspended in 
50% EtOH and applied to a preconditioned Sephadex LH-20 column, which was washed with 50% 
EtOH to remove low molecular weight phenolics (anthocyanins and flavonol glycosides). Remaining 
proanthocyanidins that adsorbed to the LH-20 column were eluted with 70% aqueous acetone. Elution 
of the proanthocyanidins was monitored using diode array detection at 280 nm. The absence of 
absorption at 360 and 450 nm confirmed that anthocyanins and flavonol glycosides were successfully 
removed. Acetone was removed under reduced pressure, and the resulting purified proanthocyanidin 
extract was freeze-dried. The presence of proanthocyanidins with A-type linkages was confirmed using 
matrix-assisted laser desorption ionization (MALDI-TOF MS) or electrospray ionization (DI/ESI MS) 
as previously described [61]. To summarize, current technologies including 
13C NMR, electrospray 
mass spectrometry, MALDI-TOF MS, and acid-catalyzed degradation with phloroglucinol have been 
employed to characterize the profile and concentration of proanthocyanidins present in the extract 
under evaluation [63-65]. As previously reported, the proanthocyanidin molecules consisted of 
epicatechin units with mainly DP of 4 and 5 containing at least one A-type linkage [64]. 
3.3. Flow cytometry analysis of cellular apoptosis 
NCI-H460 cells (1.5 × 10
6 cells) were incubated for 24 hours before PAC [0.25 or 50 µg/mL of 
media] or vehicle (<0.001% ETOH) was added. Apoptosis was evaluated in at least triplicate at each 
time point which included 2, 6, 12, 24, and 48 hours post-treatment using Annexin V-FITC staining Molecules 2011, 16                                       
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methods and counted using a FACSCalibur flow cytometer with a minimum of 10,000 cells counted 
[66]. Analysis of apoptosis was performed using WinMDI software (Joseph Trotter; 
http://pingu.salk.edu.software.html) and ModFit LT software (Verity Software, Topsham, ME, USA). 
3.4. Western blot analysis 
NCI-H460 cells (1.0 × 10
6) were incubated for 24 hours, rinsed with PBS, treated with PAC (0.25 
or 50 µg/mL) or vehicle (<0.001% ETOH) and harvested at 0, 3, 6, 24, 48 and 72 hours post-treatment. 
Cell lysates were prepared using Cell Signaling lysis buffer. Protein was quantified using the Quick 
Start Bradford Protein Assay Kit (BioRad) and equivalent protein amounts were loaded into precast 
NuPage Novex Bis-Tris 10% gels (Invitrogen). Immunoblot was performed using commercially 
available antibodies from Santa Cruz Biotechnology (Santa Clara, CA, USA) to proteins of interest 
including P21 (sc-6246), Cytochrome C (sc-13156), PARP1 (sc-8007), and GAPDH (sc-32233) as 
loading control. Expression values were determined by chemiluminescent immunodetection and 
normalized to GAPDH. Fold-change from baseline or first detection level was calculated. Positive 
fold-change values indicate increased expression.  
3.5. Isolation of RNA and synthesis of cDNA 
Total RNA was prepared from cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and 
quantity and quality were determined by Nanodrop using the Bioanalyzer 2100 capillary 
electrophoresis system (Agilent) at the Ohio State University (OSU) Microarray Core. Reverse 
transcription of purified RNA to cDNA was generated using 1.0 µg of total RNA, oligo(dT), and 
random hexamers (Applied Biosystems, Foster City, CA, USA) as primers for first strand cDNA 
synthesis under the following conditions: 30 °C for 5 minutes, 37ºC for 15 minutes, 42 °C for   
60 minutes, 50 °C for 10 minutes, and 70 °C for 15 minutes. The first strand synthesis product was 
treated with RNase H (15 minutes, 37 °C) prior to use in the real-time reaction.  
3.6. Microarray studies 
NCI-H460 lung cancer cells (2.0 × 10
6 cells) were treated with vehicle or PAC [50 µg/mL] for  
6 hours. One microgram of RNA per condition was reverse-transcribed, labeled by incorporating 
biotinylated nucleotides during in vitro transcription, and hybridized to the human U133 2.0 Plus chip 
per manufacturer recommendations (Affymetrix, Santa Clara, CA, USA). Specific transcripts bound to 
the corresponding oligonucleotide probes and the biotinylated cRNA bound fragments were detected 
using a streptavidin-antibody-phycoerythrin conjugate.  
3.7. Validation by Real Time PCR 
Real time PCR for differentially expressed genes of interest was performed utilizing RT² Profiler 
PCR Arrays (SABiosciences; Fredrick, MD, USA) and the iCycler IQ (Bio-Rad) to perform real-time 
PCR. Specifically, the apoptosis and cell cycle PCR pathway focused ‘Profiler Arrays’ were utilized 
permitting evaluation of 84 pathway linked probes for gene expression profiling. Relative changes in 
gene expression were calculated by 2 
- ∆∆Ct, where ∆∆Ct = ∆Ct (treated) – ∆Ct (untreated). Data were Molecules 2011, 16                                       
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normalized to expression levels of a combination of control genes including HPRT1, RPL13A and 
GAPDH. 
3.8. Statistical and microarray analysis 
Results are presented as the mean value ± SD for the apoptosis experiments. Data were evaluated 
for statistical significance using the Student’s t test (two-sided, p < 0.05). Microarray data was 
analyzed utilizing previously described techniques [67-71]. Briefly, analysis was performed utilizing 
unbiased differential gene expression, comparing relative fluorescence intensities between arrays, and 
Affymetrix images were transformed into CEL files utilizing GCOS software (Affymetrix). Gene 
expression levels were estimated from GeneChip probe intensities using the WEDGE++ algorithm 
[69]. WEDGE++ computes p-values based on nonparametric probe-level multi-array chi-square tests 
for differential gene expression. Next, two-fold differentially expressed genes were analyzed using 
Expression Analysis Systemic Explorer (Ease software, DAVID 6.7, updated March 2009; 
http://david.abcc.ncifcrt.gov/) [67,71] to identify over-represented biologic themes classified by gene 
ontology categories. Signaling pathways were further investigated by viewing the PANTHER (Protein 
ANalysis THrough Evolutionary Relationships) biological processes which is linked to the DAVID 
website. PANTHER is a database of phylogenestic trees of protein-coding gene families supporting a 
number of database identifiers [71,72]. 
4. Conclusions  
In summary, the present study demonstrates that cranberry proanthocyanidins significantly 
modulate cancer-related biological processes and key signaling pathways in NCI-H460 lung cancer 
cells following a single exposure at a behaviorally achievable concentration. PAC had highly 
significant and rapid apoptosis inducing effects and potent effects on multiple cell cycle linked genes 
resulting in decreased cell proliferation and increased cell death. Specifically, PAC increased P21 
expression levels, which has been linked to apoptosis resistance; thus, PAC may hold promise as a 
chemopreventive agent during the early phases of carcinogenesis or may act to re-sensitize cancer cells 
to apoptosis and chemosensitivity. Further investigation of PACs potential to induce autophagy is also 
warranted given PACs rapid induction of cell death and up-regulation of p73, a gene linked to both 
type 1 and type 2 cell death. Mechanistic research on PACs cancer inhibitory potential is ongoing in a 
larger panel of aerodigestive tract cell lines.  
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